 The goal of this clinical research study is to find the highest tolerable dose of the combination of dasatinib, cyclophosphamide, and temsirolimus that can be given to patients with advanced solid tumors. The safety of this drug combination will be studied. As secondary aim the study will evaluate treatment response to this combination and biological markers. 